Product Description

Armodafinil 150mg 30 Tablets

Armodafinil 150mg 30 Tablets is a prescription wakefulness-promoting agent (eugeroic) indicated for treating excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work disorder (SWD). As the biologically active ($R$)-enantiomer of racemic modafinil, Armodafinil provides long-lasting plasma concentrations, offering a steady therapeutic effect throughout the day under professional medical supervision.

Mechanism of Action: How Armodafinil Works

Armodafinil exerts its eugeroic effects by binding to dopamine transporters (DAT) and inhibiting dopamine reuptake in key subcortical brain structures. This targeted neurochemical action elevates extracellular dopamine concentrations without causing widespread central nervous system excitation.

• Sustained Plasma Levels: Reaches peak plasma concentration in 2 to 4 hours, maintaining higher systemic exposure late in the day compared to modafinil.

• Targeted Neural Signaling: Modulates orexin and histamine pathways in the hypothalamus, promoting natural alertness and cognitive vigilance.

Dosing and Administration Guidelines

A standard 30-tablet supply provides a full 1-month treatment protocol when taken according to prescribed medical recommendations.

Note: Dosage adjustments may be required for elderly patients or individuals with severe hepatic impairment.

Side Effects and Safety Warnings

While generally well tolerated, Armodafinil 150mg carries specific clinical risks that require careful patient compliance and monitoring.

Common Adverse Reactions

• Headache, dizziness, and mild insomnia

• Nausea, dry mouth, and loss of appetite

• Nervousness or mild anxiety

Critical Clinical Warnings

• Severe Dermatological Reactions: Discontinue immediately if a rash, mucosal lesions, or signs of severe hypersensitivity (e.g., Stevens-Johnson syndrome) occur.

• Cardiovascular Risks: Monitor blood pressure and heart rate closely, particularly in patients with pre-existing cardiovascular conditions or hypertension.

• Hormonal Contraceptive Interactions: Armodafinil induces CYP3A4 enzymes, reducing the efficacy of steroidal contraceptives during therapy and for one month following discontinuation.